Abivax Stock Drops After Late-Stage Trial Shows Cancer Cases in Higher-Dose Group
Abivax's stock fell by up to 40% after the company released late-stage trial data for its ulcerative colitis drug, obefazimod. The results showed strong efficacy but also cancer cases among patients receiving a higher dose of the medication.
Tickers: $ABVX
Topics: biotech cancer_signal drug_safety ulcerative_colitis